A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug

Long-acting cabotegravir (CAB) extends antiretroviral drug (ARV) administration from daily to monthly. However, dosing volumes, injection site reactions, and health care oversight are obstacles towards broad usage. The creation of poloxamer-coated hydrophobic and lipophilic CAB prodrugs with control...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Tanmay A., Bade, Aditya N., Sillman, Brady, Dyavar Shetty, Bhagya Laxmi, Wojtkiewicz, Melinda S., Gautam, Nagsen, Hilaire, James R., Sravanam, Sruthi, Szlachetka, Adam, Lamberty, Benjamin G., Morsey, Brenda M., Fox, Howard S., Alnouti, Yazen, McMillan, JoEllyn M., Mosley, R. Lee, Meza, Jane, Domanico, Paul L., Yue, Tai-Yuen, Moore, Gary, Edagwa, Benson J., Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384935/
https://www.ncbi.nlm.nih.gov/pubmed/32341511
http://dx.doi.org/10.1038/s41563-020-0674-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384935/
https://www.ncbi.nlm.nih.gov/pubmed/32341511
http://dx.doi.org/10.1038/s41563-020-0674-z

Ejemplares similares